Shaomeng Wang

40.4k total citations · 9 hit papers
459 papers, 29.3k citations indexed

About

Shaomeng Wang is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Shaomeng Wang has authored 459 papers receiving a total of 29.3k indexed citations (citations by other indexed papers that have themselves been cited), including 355 papers in Molecular Biology, 128 papers in Oncology and 49 papers in Organic Chemistry. Recurrent topics in Shaomeng Wang's work include Ubiquitin and proteasome pathways (89 papers), Cell death mechanisms and regulation (79 papers) and Protein Degradation and Inhibitors (78 papers). Shaomeng Wang is often cited by papers focused on Ubiquitin and proteasome pathways (89 papers), Cell death mechanisms and regulation (79 papers) and Protein Degradation and Inhibitors (78 papers). Shaomeng Wang collaborates with scholars based in United States, China and Canada. Shaomeng Wang's co-authors include Renxiao Wang, Chao‐Yie Yang, Yipin Lu, Sanjeev Shangary, Xueliang Fang, Zaneta Nikolovska‐Coleska, Jeanne A. Stuckey, Longchuan Bai, Luhua Lai and Denzil Bernard and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Shaomeng Wang

452 papers receiving 28.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Further development and validation of empirical scoring functions for structure-based binding affinity prediction

2002 954 citations Shaomeng Wang et al. profile →
The PDBbind Database: Collection of Binding Affinities for Protein−Ligand Complexes with Known Three-Dimensional Structures

2004 791 citations Yipin Lu, Shaomeng Wang et al. profile →
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

2014 737 citations Irfan A. Asangani, Rohit Malik et al. profile →
Comparative Evaluation of 11 Scoring Functions for Molecular Docking

2003 706 citations Yipin Lu, Shaomeng Wang et al. profile →
The PDBbind Database: Methodologies and Updates

2005 630 citations Yipin Lu, Chao‐Yie Yang et al. profile →
Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

2006 602 citations Ke Ding, Yipin Lu et al. profile →
Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors

2005 564 citations Ke Ding, Yipin Lu et al. Journal of the American Chemical Society profile →
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

2019 440 citations Longchuan Bai, Donna McEachern et al. profile →
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

2019 303 citations Chao‐Yie Yang, Jeanne A. Stuckey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shaomeng Wang United States	91	20.8k	7.0k	5.4k	4.6k	1.9k	459	29.3k
Stefan Knapp Germany	91	21.6k 1.0×	5.6k 0.8×	3.7k 0.7×	2.1k 0.5×	1.1k 0.6×	516	29.0k
Stephen W. Fesik United States	86	24.8k 1.2×	5.3k 0.8×	3.1k 0.6×	2.7k 0.6×	2.5k 1.3×	267	31.1k
Paul Workman United Kingdom	85	18.6k 0.9×	5.8k 0.8×	2.7k 0.5×	2.6k 0.6×	4.4k 2.4×	535	27.7k
Nathanael S. Gray United States	104	30.5k 1.5×	10.9k 1.6×	5.0k 0.9×	2.3k 0.5×	3.0k 1.6×	476	42.2k
Kevan M. Shokat United States	96	24.3k 1.2×	6.9k 1.0×	2.4k 0.4×	1.6k 0.4×	2.4k 1.3×	305	34.2k
Steven A. Carr United States	108	31.7k 1.5×	5.4k 0.8×	2.1k 0.4×	1.5k 0.3×	4.0k 2.2×	372	44.4k
Neal Rosen United States	100	24.7k 1.2×	12.2k 1.7×	2.0k 0.4×	2.4k 0.5×	4.2k 2.3×	255	34.8k
Tom L. Blundell United Kingdom	94	34.2k 1.6×	3.5k 0.5×	3.3k 0.6×	5.3k 1.2×	1.5k 0.8×	505	45.7k
Edward A. Sausville United States	92	19.3k 0.9×	11.7k 1.7×	2.7k 0.5×	1.0k 0.2×	3.4k 1.8×	329	30.9k
Olivier Michielin Switzerland	66	14.7k 0.7×	9.1k 1.3×	7.0k 1.3×	7.3k 1.6×	1.2k 0.7×	278	35.6k

Countries citing papers authored by Shaomeng Wang

Since Specialization

Citations

This map shows the geographic impact of Shaomeng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaomeng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaomeng Wang more than expected).

Fields of papers citing papers by Shaomeng Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaomeng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaomeng Wang. The network helps show where Shaomeng Wang may publish in the future.

Co-authorship network of co-authors of Shaomeng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Shaomeng Wang. A scholar is included among the top collaborators of Shaomeng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaomeng Wang. Shaomeng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Zhaocheng, Kristy A. Warner, Andréa Mantesso, et al.. (2022). p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness. Clinical Cancer Research. 28(21). 4757–4770. 13 indexed citations

Hu, Nan, Fangyang Wang, Tianyu Sun, et al.. (2021). Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clinical Cancer Research. 27(8). 2301–2313. 19 indexed citations

Kregel, Steven, Rohit Malik, Irfan A. Asangani, et al.. (2019). Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 25(13). 4038–4048. 26 indexed citations

Warner, Kristy A., Alexander T. Pearson, Felipe Nör, et al.. (2018). Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2–p53 Interaction in Mucoepidermoid Carcinoma. Clinical Cancer Research. 25(5). 1588–1600. 18 indexed citations

Nör, Felipe, Kristy A. Warner, Zhaocheng Zhang, et al.. (2016). Therapeutic Inhibition of the MDM2–p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clinical Cancer Research. 23(4). 1036–1048. 33 indexed citations

Lü, Jianfeng, Donna McEachern, Shunqiang Li, Matthew J. Ellis, & Shaomeng Wang. (2016). Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. 15(12). 2887–2893. 30 indexed citations

Jin, Meiyan, Luke F. Peterson, Denzil Bernard, et al.. (2016). Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. Clinical Cancer Research. 22(21). 5383–5393. 35 indexed citations

Warner, Kristy A., Felipe Nör, Manoela Domingues Martins, et al.. (2016). Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clinical Cancer Research. 22(14). 3550–3559. 17 indexed citations

Bi, Xiuli, Xin Song, Nicole M. Pohl, et al.. (2013). A sequence variant in the phospholipase C epsilon C2 domain is associated with esophageal carcinoma and esophagitis. Molecular Carcinogenesis. 52(S1). 80–86. 14 indexed citations

10.

Bai, Longchuan, Donna McEachern, Chao‐Yie Yang, et al.. (2012). LRIG1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNFα Expression and Receptor Tyrosine Kinase Signaling. Cancer Research. 72(5). 1229–1238. 28 indexed citations

11.

Imai, Atsushi, Benjamin D. Zeitlin, Fernanda Visioli, et al.. (2011). Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects. Cancer Research. 72(3). 716–725. 14 indexed citations

12.

Yang, Jie, Donna McEachern, Wenyan Li, et al.. (2011). Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases. Molecular Cancer Therapeutics. 10(4). 658–669. 43 indexed citations

13.

Lü, Jianfeng, Donna McEachern, Haiying Sun, et al.. (2011). Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment. Molecular Cancer Therapeutics. 10(5). 902–914. 51 indexed citations

14.

Wang, Zhiwei, Asfar S. Azmi, Aamir Ahmad, et al.. (2009). TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway. Cancer Research. 69(7). 2757–2765. 69 indexed citations

15.

Wang, Zhen, Min Zheng, Zhichuan Li, et al.. (2009). Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research. 69(16). 6556–6564. 83 indexed citations

16.

Zeitlin, Benjamin D., Zhaocheng Zhang, Kristy A. Warner, et al.. (2009). TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Molecular Cancer Therapeutics. 8(4). 893–903. 38 indexed citations

17.

Shangary, Sanjeev, Ke Ding, Su Qiu, et al.. (2008). Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Molecular Cancer Therapeutics. 7(6). 1533–1542. 75 indexed citations

18.

Lü, Jianfeng, Longchuan Bai, Haiying Sun, et al.. (2008). SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP. Cancer Research. 68(22). 9384–9393. 174 indexed citations

19.

Verhaegen, Monique, Joshua A. Bauer, Cristina Martín de la Vega, et al.. (2006). A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase–Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species. Cancer Research. 66(23). 11348–11359. 117 indexed citations

20.

Sadowsky, Jack, Margaret A. Schmitt, Hee‐Seung Lee, et al.. (2005). Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-x _L : Critical Role of the Molecular Scaffold in Protein Surface Recognition. Journal of the American Chemical Society. 127(34). 11966–11968. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact